Roche will acquire Saga Diagnostics via its Foundation Medicine unit in a deal valued at up to $595 million to expand cancer MRD testing. Foundation Medicine says the transaction will bring Saga’s Pathlight tumor-informed MRD platform into its diagnostics portfolio, including plans to use Roche sequencing and digital PCR systems for more scalable MRD workflows. Pathlight reportedly combines whole-genome sequencing and digital PCR to identify and track structural variants for ultra-sensitive MRD detection. Foundation Medicine also said Pathlight is available in the US for breast and colorectal cancer MRD testing, with coverage for recurrence monitoring in early-stage breast cancer subtypes. Roche expects the transaction to close in Q3 and integrate Pathlight into Foundation Medicine afterward, aiming to broaden MRD applicability across tumor types and accelerate decentralized testing capabilities.